Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 29 January 2013
Vol. 6, Issue 260, p. pc3
[DOI: 10.1126/scisignal.2003968]


Science Signaling Podcast: 29 January 2013

Friedegund Meier1 and Annalisa M. VanHook2

1 Division of Dermatologic Oncology, Department of Dermatology, University of Tübingen, 72076 Tübingen, Germany.
2 Web Editor, Science Signaling, American Association for the Advancement of Science, 1200 New York Avenue, NW, Washington, DC 20005, USA.

Abstract: This Podcast features an interview with Friedegund Meier, senior author of a Research Article that appears in the 29 January 2013 issue of Science Signaling. Beck et al. focuses on the role of endoplasmic reticulum (ER) stress in tumor cell killing by the drug vemurafenib. Vemurafenib is an effective therapy for melanomas that harbor a particular mutant form of the kinase BRAF, but melanomas often develop resistance to the drug, thus reducing its efficacy. The authors found that, in addition to inhibiting survival signaling mediated by the kinase ERK, vemurafenib also triggered apoptosis by inducing ER stress. Treating vemurafenib-resistant melanoma cells with an ER stress inducer in combination with vemurafenib improved cell killing, suggesting that this might be an effective combined therapy for treating melanoma.

Citation: F. Meier, A. M. VanHook, Science Signaling Podcast: 29 January 2013. Sci. Signal. 6, pc3 (2013).

Read the Full Text

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882